图片来源:视觉中国界面新闻记者 |唐卓雅界面新闻编辑 |谢欣5月20日,国家药监局审评中心官网公示,科济药业的1类新药舒瑞基奥仑赛注射液拟被纳入优先审评,用于治疗CLDN18.2表达阳性、至少二线治疗失败的晚期胃/食管胃结合部腺癌。图片来源:国家药监局药品审评中心官网5月21日港股开盘,科济药业涨幅最高达6.49%。截至收盘,科济药业涨3.85%,报21.6港元/股,当前市值为124亿港元。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.